VRCCO is currently enrolling; confirm WSU intake separately
What is being offered: One local T-cell-engager protocol, AVMA study 534230, previously represented by two active catalog records. Current VRCCO primary evidence describes CD3/CD28 T-cell engagement targeting B7-H3/PD-L1, injected into the tumor, followed by standard surgical removal approximately one week later. There is no placebo. VRCCO eligibility includes cutaneous soft tissue sarcoma over 1.7 cm and body weight at least 5 kg. Previously published WSU criteria required easily accessible STS at least 2 cm; the WSU page could not be read in this audit, so its present intake and site-specific criteria require confirmation. Do not apply VRCCO-specific thresholds to the unverified WSU cohort.
Who may qualify: Confirmed cancer diagnosis required; Measurable; Planned surgery; Min weight kg: 5
Costs / coverage: VRCCO provides a $1,500 surgery credit and covers study-related ICU stays, bloodwork and medications. The previously published WSU offer was a $1,000 medical credit plus study-related ICU, medications and bloodwork; that WSU offer was not independently reverified today. Owners pay uncovered standard surgical/diagnostic care.
Contact: VRCCO / Dr. Kristen Couto — official clinical-trial page. WSU: Jennifer Heusser — jpmarcus3@wsu.edu; 509-592-3668; current WSU intake needs reconfirmation.
Participating locations
- WSU Veterinary Teaching Hospital, 205 Ott Rd, Pullman, WA 99164
- VRCCO East, 62889 NE Oxford Ct, Bend, OR 97701